In May 2014, Fertility Focus first funding round successfully raised £880,500 to invest in marketing for its fertility monitor.
Fertility Focus is driven by the ultimate goal of increasing pregnancy rates in infertile couples by up to 50%.
The business brings a brand new approach to the issue of infertility diagnosis and treatment, with two products; the OvuSense – the world’s most accurate fertility monitor – and the FertiloScope, a unique minimally invasive instrument for the early diagnosis and immediate corrective surgery of the physical causes of female infertility.Robert Milnes, CEO, has 23 years’ experience in the healthcare sector, with over 13 years’ experience in women’s health alone. He has worked for Roche, Oxford Instruments and Huntleigh Healthcare.
This round was led by Steve Godber and Christine Soden, who are both experienced MedTech executives, and Angel CoFund, as well as Norgenix, Fertility Focus Ltd’s strategic US distribution partner, and Midven, the leading Venture Capitalist fund in the Midlands.
Where are they now?
Fertility Focus has since closed a second funding round on SyndicateRoom).